After-Hours Stock Movers 11/02: (IQNT) (AUPH) (KTOS) Higher; (FIT) (DPLO) (FB) Lower (more...)

November 2, 2016 6:27 PM EDT

Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.

Today's After-Hours Moves

Inteliquent, Inc. (NASDAQ: IQNT) 33.6% HIGHER; entered into a definitive agreement to be acquired by an affiliate of GTCR LLC, a leading private equity firm, and merged with a subsidiary of Onvoy, LLC a fast-growing leader in Communications Enablement services. Under the terms of the agreement, Inteliquent stockholders of record will receive $23.00 in cash per share of common stock, which represents a 37% premium to Inteliquents closing stock price on November 1, 2016. The value of the transaction is approximately $800 million.

Fitbit (NYSE: FIT) 29.5% LOWER; reported Q3 EPS of $0.19, in-line with the analyst estimate of $0.19. Revenue for the quarter came in at $503.8 million versus the consensus estimate of $506.93 million. GUIDANCE: Fitbit sees Q4 2016 EPS of $0.14-$0.18, versus the consensus of $0.75. Fitbit sees Q4 2016 revenue of $725-750 million, versus the consensus of $985.1 million. Fitbit sees FY2016 EPS of $0.55-$0.59, versus the consensus of $1.18. Fitbit sees FY2016 revenue of $2.32-2.35 billion, versus the consensus of $2.58 billion.

Diplomat Pharmacy (NYSE: DPLO) 27.8% LOWER; reported Q3 EPS of $0.21, $0.03 worse than the analyst estimate of $0.24. Revenue for the quarter came in at $1.18 billion versus the consensus estimate of $1.26 billion. GUIDANCE: Diplomat Pharmacy sees FY2016 EPS of $0.83-$0.87, versus the consensus of $0.93. Diplomat Pharmacy sees FY2016 revenue of $4.4-4.6 billion, versus the consensus of $4.67 billion.

Aurinia Pharmaceuticals Inc. (Nasdaq: AUPH) 19.5% HIGHER; announced its plans for a single Phase III clinical trial for voclosporin in the treatment of lupus nephritis (LN). Pursuant to its recent End of Phase II meeting with the U.S. Food & Drug Administration (FDA) Division of Pulmonary, Allergy and Rheumatology Products, Aurinia believes this Phase III clinical trial whose design is consistent with the ongoing AURA study, will support a New Drug Application (NDA) submission.

Pacific Bio (NASDAQ: PACB) 11.8% LOWER; reported Q3 EPS of ($0.19), $0.01 better than the analyst estimate of ($0.20). Revenue for the quarter came in at $25.1 million versus the consensus estimate of $24.68 million.

Axcelis Technologies (NASDAQ: ACLS) 10.4% LOWER; reported Q3 EPS of $0.07, $0.03 better than the analyst estimate of $0.04. Revenue for the quarter came in at $67.5 million versus the consensus estimate of $67.74 million. GUIDANCE: Axcelis Technologies sees Q4 2016 EPS of $0.04-$0.08, versus the consensus of $0.15. Axcelis Technologies sees Q4 2016 revenue of $65-70 million, versus the consensus of $75.14 million.

Kratos Defense (NASDAQ: KTOS) 10.3% HIGHER; reported Q3 EPS of $0.03, $0.08 better than the analyst estimate of ($0.05). Revenue for the quarter came in at $165.4 million versus the consensus estimate of $162.1 million. GUIDANCE: Kratos Defense sees FY2016 revenue of $665 million, versus the consensus of $659.1 million.

Intersect ENT (NASDAQ: XENT) 10.2% HIGHER; reported Q3 EPS of ($0.22), $0.05 better than the analyst estimate of ($0.27). Revenue for the quarter came in at $18.5 million versus the consensus estimate of $17.84 million.

Amyris (NASDAQ: AMRS) 9.7% HIGHER; reported Q3 EPS of ($0.07), $0.01 worse than the analyst estimate of ($0.06). Revenue for the quarter came in at $26.5 million versus the consensus estimate of $33.61 million.

Zumiez Inc. (NASDAQ: ZUMZ) 9.5% HIGHER; comparable sales increased 10.2% for the four-week period compared to a comparable sales decrease of 8.1% in the year ago period. Raises outlook.

Microsemi (NASDAQ: MSCC) 9.3% HIGHER; reports from Bloomberg the company is exploring a sale after being approached by Skyworks.

Facebook (NASDAQ: FB) 8.2% LOWER; reported Q3 EPS of $1.09, $0.12 better than the analyst estimate of $0.97. Revenue for the quarter came rose 56% to $7.011 billion versus the consensus estimate of $6.92 billion. Warns growth to slow.

Hudson Technologies (NASDAQ: HDSN) 6.2% HIGHER; reported Q3 EPS of $0.14, $0.05 better than the analyst estimate of $0.09. Revenue for the quarter came in at $34.9 million versus the consensus estimate of $28.22 million.

Wynn Resorts Ltd (NASDAQ: WYNN) 5.4% LOWER; reported Q3 EPS of $0.75, $0.02 better than the analyst estimate of $0.73. Revenue for the quarter came in at $1.11 billion versus the consensus estimate of $1.12 billion.

Take-Two Interactive Software (NASDAQ: TTWO) 4.3% HIGHER; reported Q2 EPS of $0.45, $0.16 better than the analyst estimate of $0.29. Revenue for the quarter came in at $420.2 million versus the consensus estimate of $401.99 million. GUIDANCE: Take-Two Interactive Software sees Q3 2017 EPS of $0.30-$0.40, versus the consensus of $1.04. Take-Two Interactive Software sees Q3 2017 revenue of $475-525 million, versus the consensus of $650.1 million. Take-Two Interactive Software sees FY2017 EPS of $2.00-$2.25, versus the consensus of $1.23. Take-Two Interactive Software sees FY2017 revenue of $1.75-1.85 billion, versus the consensus of $1.64 billion.

Whole Foods Market (NASDAQ: WFM) 3.8% HIGHER; reported Q4 EPS of $0.28, $0.04 better than the analyst estimate of $0.24. Revenue for the quarter came in at $3.5 billion versus the consensus estimate of $3.5 billion. Comps fell 2.6 percent , versus a drop of 2.1 percent expected. co-founder to takeover as CEO.

AIG (NYSE: AIG) 3.4% LOWER; reported Q3 EPS of $1.10, $0.08 worse than the analyst estimate of $1.18.

Wingstop Inc. (NASDAQ: WING) 3.2% LOWER; announced that a stockholder, namely an affiliate of Roark Capital, intends to offer for sale in an underwritten secondary offering 6,765,858 shares of the Company’s common stock pursuant to the Company’s shelf registration statement filed with the Securities and Exchange Commission (“SEC”). Wingstop will not receive any proceeds from the sale of the shares by the selling stockholder in this offering.

21st Century Fox (NASDAQ: FOXA) 1.6% HIGHER; reported Q1 EPS of $0.51, $0.07 better than the analyst estimate of $0.44. Revenue for the quarter came in at $6.51 billion versus the consensus estimate of $6.49 billion.

Transocean (NYSE: RIG) 1.4% HIGHER; reported Q3 EPS of $0.25, $0.11 better than the analyst estimate of $0.14. Revenue for the quarter came in at $903 million versus the consensus estimate of $862.21 million.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Special Reports

Related Entities

GTCR, After-Hours Movers

Add Your Comment